HASBROUCK HEIGHTS, N.J., Sept. 13, 2012 (GLOBE NEWSWIRE) -- Wm Smith Special Opportunities Research Company has initiated coverage of Nymox Pharmaceutical Corporation (Nasdaq:NYMX) with a 12 month target price of $16.00. The report was written by Sameer Harish, an equity research analyst.  According to the report, Nymox "is engaged in multiple clinical programs with NX-1207, a novel candidate to treat the symptoms of benign prostatic hyperplasia (BPH) and prostate cancer. We strongly believe that NX-1207 represents a significant advancement in the treatment of Lower Urinary Tract Symptoms (LUTS) and, over time, may become standard of care for BPH."  The report estimates that "the BPH market may represent a $1 billion-plus annual opportunity for NX-1207 in the United States."

About Nymox: NX-1207 is a novel patented drug developed by Nymox which is currently in Phase 3 trials for BPH and in Phase 2 trials for low risk localized prostate cancer. The drug has successfully completed a series of blinded controlled multi-center U.S. clinical trials for BPH where a single dose of NX-1207 has been found to produce symptomatic improvements about double that reported for currently approved BPH drugs without causing the sexual or cardiovascular side effects associated with those drugs. NX-1207 is injected directly into the prostate by a urologist in an office setting and involves little or no pain or discomfort.  For more information about the NX-1207 clinical trials please go to www.clinicaltrials.gov or contact Nymox at info@nymox.com.

BPH or enlarged prostate is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80 and is associated with growth in prostate size as men age. BPH causes progressive difficulties with urination, such as nocturia, urge to void frequently, acute urinary retention and other problems. The condition can seriously impact the health and quality of life of middle aged and older men. An estimated 100 million men worldwide being estimated to suffer from BPH symptoms. More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.  Nymox made no payments to Wm Smith for the research report.

About Wm Smith Special Opportunities Research Company: Wm Smith Special Opportunities Research Company is an affiliate of Wm Smith & Co. Wm Smith & Co. is an independent research company providing objective, fundamental equity research on "special situations" (primarily under-followed and under-valued) companies to a select group of institutional clients from both the traditional and alternative investment arena. Wm Smith has no investment bank, consulting, or other revenue-generating relationship with Nymox and the analyst did not receive any compensation from the company.  For more information visit: www.wmsmith.com or call 800-757-1175.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.
CONTACT: Roy Wolvin         Nymox Pharmaceutical Corporation         1-800-93NYMOX         www.nymox.com